Keytruda (pembrolizumab)
Numéro de dossier de l’APP:
22165
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
Pembrolizumab in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD‐L1 (CPS ≥ 10) as determined by a validated test
Promoteur/fabricant:
Merck Canada Inc.
Numéro de projet de l’ACMTS:
PC0295
Lettre-contrat de l’APP:
Conclusion du processus de négociation: